Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one

Rev Neurol. 2023 Mar 16;76(6):213-216. doi: 10.33588/rn.7606.2022350.
[Article in English, Spanish]

Abstract

Efecto beneficioso del cambio a un segundo anticuerpo monoclonal anti-CGRP en pacientes con migraña no respondedores a un primero.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Migraine Disorders*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized